DBS Bank dominates LinkedIn's 2025 Top Companies in Singapore list for the third time in a row, topping the best companies for career growth in the country.

The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...

Merck, Hackensack Meridian and Atlantic Health were the only N.J. businesses to make Fortune's list of the country's best companies to work.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2025 sales and earnings conference call with institutional ...

Based on Wall Street analyst estimates for 2025 EPS, Amgen trades at 15 times its projected earnings, while Merck sits at a forward P/E of 10. By this measure, Merck is the cheaper stock and a ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. While there are concerns about its patent losses in the future, its sales are still ...

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Forbes contributors publish independent expert analyses and insights. Dr. Cheryl Robinson covers areas of leadership, pivoting and careers.